{"symbol":"AMGN","fiscalQuarter":"Q1-2026","reportDate":"2026-04-30","reportTime":"AMC","status":"reported","company":{"name":"Amgen Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/AMGN/earnings/Q1-2026","estimates":{"consensusEps":4.7629,"consensusRevenue":8582.26,"epsLow":4.17,"epsHigh":5.24,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Amgen Inc. is a leading biotechnology company focused on developing innovative therapies for serious illnesses. Operating in the Health Care sector, Amgen is known for its advancements in biologic medicines, which are crucial for treating conditions like cancer and autoimmune diseases.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of profitability and will show how well Amgen is managing its costs and generating income.","consensus":"$4.76"},{"name":"Revenue","why":"Revenue figures provide insight into the overall sales performance and market demand for Amgen's products.","consensus":"$8.6B"}],"lastQuarterRecap":{"summary":"In Q4-2025, Amgen reported an EPS of $5.29, exceeding expectations by 11.18%. Despite the positive earnings surprise, the stock experienced a slight decline the following day.","promises":[]},"wallStreetExpectations":{"summary":"Analysts are generally optimistic about Amgen's upcoming earnings, expecting solid EPS and revenue figures. The company has consistently beaten EPS estimates in recent quarters, which adds to the positive sentiment.","bullCase":"If Amgen continues its trend of beating EPS estimates, it could signal strong operational efficiency and product demand, potentially leading to a stock price increase.","bearCase":"Conversely, if Amgen fails to meet expectations or provides weak guidance, it could raise concerns about future growth, leading to a negative reaction in the stock price."},"optionsSignal":{"impliedMove":"4.3%","context":"The options market is pricing in a significant move around the earnings announcement, indicating that traders expect volatility.","historicalAvgMove":"0.8%","richness":"rich","richnessContext":"Options are pricing a 4.3% move, while the stock has averaged only 0.8% over the last 8 quarters \u2014 setup is rich."},"earningsTrackRecord":[{"quarter":"Q4-2025","epsSurprise":"+11.18%","reaction":"-1.77%"},{"quarter":"Q3-2025","epsSurprise":"+12.75%","reaction":"+0.13%"},{"quarter":"Q2-2025","epsSurprise":"+15.61%","reaction":"-0.62%"},{"quarter":"Q1-2025","epsSurprise":"+17.85%","reaction":"-2.45%"},{"quarter":"Q4-2024","epsSurprise":"+5.59%","reaction":"+0.05%"}],"pivotalQuestions":[{"question":"Will Amgen's EPS exceed the consensus estimate of $4.76?","whyItMatters":"A strong EPS performance could reinforce investor confidence and support a positive stock reaction."},{"question":"What guidance will Amgen provide for future revenue growth?","whyItMatters":"Insights into future revenue expectations will be critical for assessing the company's growth trajectory and market positioning."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $5.00 or higher would confirm the bull case, indicating strong operational performance.","bearTrigger":"An EPS below $4.50 would confirm the bear case, raising concerns about profitability.","context":"The market is debating whether Amgen can maintain its strong earnings performance amid competitive pressures and market conditions."},"scenarioPlaybook":{"beatAndRaise":"If Amgen beats expectations, history suggests a potential stock increase of around 0.6%, confirming strong operational performance.","inLineCautious":"If results are in line with expectations but management is cautious, the stock may react neutrally as investors reassess future growth.","miss":"If Amgen misses expectations, history suggests a potential decline of around 0.4%, raising concerns about future profitability."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"7 of 23 (30%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days \u2014 this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating Amgen's ability to sustain its earnings momentum, given the recent strong performance and potential for new product launches.","supportingPoints":["Amgen has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.","The options market is pricing in a larger move than historical averages, suggesting heightened expectations.","Insider trading patterns show mixed signals, which could indicate uncertainty about future performance."],"riskToConsensus":"If EPS comes in below $4.50, it could undermine the bullish sentiment and lead to a reevaluation of growth expectations."},"whatToListenFor":["Any commentary on new product launches and their expected impact on revenue.","Insights into cost management strategies and their effect on profitability.","Updates on competitive pressures in the biotechnology sector.","Any changes in guidance for future quarters, especially regarding revenue growth.","Management's view on market conditions and their potential impact on Amgen's performance."],"metaDescription":"Amgen (AMGN) reports Q1 2026 earnings April 30. Analysts expect $4.76 EPS on $8.6B revenue. Here's what to watch."},"postBrief":{"headline":"Amgen Beats on EPS, Stock Up 2.43%","keyNumbers":[{"metric":"EPS","actual":"$5.15","expected":"$4.76","surprise":"+8.88%"},{"metric":"Revenue","actual":"N/A","expected":"$8.6B","surprise":"N/A"}],"managementCommentary":{"tone":"Unknown","keyQuotes":[],"summary":"No transcript is on record, and the analysis is based on numerical results only."},"guidanceChanges":{"summary":"No guidance data is available.","changes":[]},"whatItMeans":"Amgen's earnings report showed a strong performance on EPS, exceeding expectations by nearly 9%. This positive surprise contributed to a 2.43% increase in the stock price. However, the lack of revenue data and management commentary leaves some uncertainty about the overall business outlook.","metaDescription":"Amgen Inc. (AMGN) Q1 2026 earnings: EPS beat by 8.88%. Stock up 2.43%. Full breakdown."}}